Introduction PIROXICAM
XX is a nonsteroidal anti-inflammatory drugs (NSAIDs), possesses analgesic and antipyretic properties. XX is structurally unrelated to other NSAIDs. It has a long half-life and may be administered as a single daily dose, which can be an advantage over other NSAIDs. The anti-inflammatory potential of it has been equated with that of indomethacin, and its analgesic activity has been shown to be greater than that of aspirin. XX is indicated in the treatment of osteoarthritis and rheumatoid arthritis. It was approved by the FDA in 1982. The anti-inflammatory effects of it may result from the peripheral inhibition of prostaglandin synthesis due to the inhibition of the enzyme cyclooxygenase. It also can inhibit the activation of neutrophils, which may contribute to antiinflammatory effects as well. Prostaglandins sensitize pain receptors, and their inhibition is believed to be responsible for the analgesic effects of it. |
Category: - Analgesics, antipyretics, NSAIDs, antigout, and antirheumatics
- Non-opioid analgesics
- Non steroidal anti-inflammatory drugs (NSAIDs)
- Analgesics, antipyretics, NSAIDs, antigout, and antirheumatics
- Antirheumatics, topical
|
Primary Characterstics Piroxicam is of Synthetic origin and belongs to Oxicam. It belongs to Cyclo-oxygenase inhibitor pharmacological group on the basis of mechanism of action and also classified in Analgesics and Anti-inflammatory Agents pharmacological group.The Molecular Weight of Piroxicam is 331.30. Its pKa is 6.3. |
Pharmacokinetics Oral absorption of Piroxicam is found to be 100% . Volume of distribution is found to be 0.1 l/kg and plasma protien binding is 99 %. Renal Excretion accounts for 10 % and plasma half life is 30 - 60 hr.
|